• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CDK4 Gene Record

  • Summary
  • Interactions
  • Claims
  • CDK4 1019 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    1019
    CYCLIN DEPENDENT KINASE 4
    CDK4
    CMM3
    PSK-J3
    123829
    1773
    ENSG00000135446
    OTTHUMG00000170382
    CDK 4,6
    CDK 1,2,4,5,6,7,9 (pan-CDK)
    P11802
    cyclin-dependent kinase 4
    CDK4_HUMAN
    CELL DIVISION PROTEIN KINASE 4
    CELL DIVISION PROTEIN KINASE 4 (EC 2.7.1.37) (CYCLIN-DEPENDENT KINASE 4) (PSK-J3). [SOURCE:UNIPROT/SWISSPROT;ACC:P11802]
    13
    PA102
    T85799

    Gene Info:

    Interpro Type Domain
    Uniprot Status Swiss-Prot
    Interpro Name Serine/threonine- / dual-specificity protein kinase, catalytic domain
    Human Readable Name DRUGGABLE GENOME
    Interpro Acc IPR002290
    Human Readable Name KINASE
    Interpro Short Name Ser/Thr_dual-sp_kinase_dom
    Uniprot Evidence 1: Evidence at protein level
    Target Class Enzymes
    Target Subclass EC:2.7.11.22
    CancerCommons Reported Gene Name CDK4/6
    CancerCommons Reported Gene Name Pan CDK
    Initial Gene Query CDK4
    Counted Citations from 1950-2000 3030
    Gene Biotype PROTEIN_CODING
    (23 More Sources)

    Gene Categories: Category Details

    TRANSCRIPTION FACTOR COMPLEX
    TUMOR SUPPRESSOR
    KINASE
    SERINE THREONINE KINASE
    DRUG RESISTANCE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE
    TRANSCRIPTION FACTOR

    Publications:

    Dickson et al., 2016, Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial., JAMA Oncol
    Dickson et al., 2013, Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma., J. Clin. Oncol.
    Perez et al., 2015, Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA., Oncotarget
    Fry et al., 2004, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts., Mol. Cancer Ther.
    Reddy MV et al., 2014, Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)., J Med Chem
    Logan et al., 2013, PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity., Anticancer Res.
    Olanich ME et al., 2015, CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma., Clin Cancer Res
    Rocca A et al., 2017, Progress with palbociclib in breast cancer: latest evidence and clinical considerations., Ther Adv Med Oncol
    Burgess A et al., 2006, Inhibition of S/G2 phase CDK4 reduces mitotic fidelity., J Biol Chem
    Gelbert et al., 2014, Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine., Invest New Drugs
    Vora et al., 2014, CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors., Cancer Cell
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Rhee et al., 1995, c-Myc and cyclin D3 (CcnD3) genes are independent targets for glucocorticoid inhibition of lymphoid cell proliferation., Cancer Res.
    Bortolozzi R et al., 2018, Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All)., Biochem Pharmacol
    Swarbrick et al., 2000, Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells., Mol. Cell. Biol.
    Rader et al., 2013, Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma., Clin. Cancer Res.
    Banerji et al., 2005, Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models., Clin. Cancer Res.
    Park et al., 2000, Involvement of retinoblastoma family members and E2F/DP complexes in the death of neurons evoked by DNA damage., J. Neurosci.
    Montagnoli A et al., 2008, A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity., Nat Chem Biol
    Frazer-Abel et al., 2004, Nicotine activates nuclear factor of activated T cells c2 (NFATc2) and prevents cell cycle entry in T cells., J. Pharmacol. Exp. Ther.
  • CHEMBL1956070   CDK4

    Interaction Score: 4.26

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    16476733


    Sources:
    DTC

  • CHEMBL1956069   CDK4

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16476733


    Sources:
    DTC

  • VORUCICLIB   CDK4

    Interaction Score: 2.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • G1T28-1   CDK4

    Interaction Score: 2.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • AG-24322   CDK4

    Interaction Score: 1.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • RIVICICLIB   CDK4

    Interaction Score: 1.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • RIBOCICLIB   CDK4

    Interaction Score: 1.2

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name LEE011
    Novel drug target Novel Target
    Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor

    PMIDs:
    24045179 29408328 25810375


    Sources:
    ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial ChemblInteractions CIViC TTD

  • RIBOCICLIB SUCCINATE   CDK4

    Interaction Score: 1.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LEROCICLIB   CDK4

    Interaction Score: 1.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ABEMACICLIB   CDK4

    Interaction Score: 0.91

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma
    Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor
    Direct Interaction yes

    PMIDs:
    24919854


    Sources:
    ClearityFoundationBiomarkers ChemblInteractions CancerCommons TTD OncoKB

  • RG-547   CDK4

    Interaction Score: 0.71

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TRILACICLIB   CDK4

    Interaction Score: 0.71

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • PALBOCICLIB   CDK4

    Interaction Score: 0.7

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma
    Mechanism of Interaction CDK4/cyclin D1 inhibitor
    Direct Interaction yes

    PMIDs:
    27124835 23569312 26528855 15542782 24417566 23898052 25810375 28203301


    Sources:
    DTC MyCancerGenome ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial OncoKB

  • RGB-286638   CDK4

    Interaction Score: 0.61

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • ALVOCIDIB   CDK4

    Interaction Score: 0.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor
    Direct Interaction yes
    Novel drug target Novel Target

    PMIDs:
    11752352


    Sources:
    DTC MyCancerGenome TdgClinicalTrial ChemblInteractions

  • MILCICLIB   CDK4

    Interaction Score: 0.53

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • APREMILAST   CDK4

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TANESPIMYCIN   CDK4

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16203796


    Sources:
    NCI

  • PHA-793887   CDK4

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • ALPELISIB   CDK4

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25002028


    Sources:
    CIViC

  • CAMPTOTHECIN   CDK4

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10777774


    Sources:
    NCI

  • UCN-01   CDK4

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • RONICICLIB   CDK4

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • AZD-5438   CDK4

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Cyclin-dependent kinase inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DEXAMETHASONE   CDK4

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7664296 29408328


    Sources:
    NCI CIViC

  • AT-7519   CDK4

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Cyclin-dependent kinase inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • NICOTINE   CDK4

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15231866


    Sources:
    NCI

  • CHEMBL225519   CDK4

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18469809


    Sources:
    DTC

  • PROGESTERONE   CDK4

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10713180


    Sources:
    NCI

  • Ensembl: ENSG00000135446

    • Version: 101_38

    Alternate Names:
    CDK4 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • HopkinsGroom: P11802

    • Version: 11-September-2012

    Alternate Names:
    CDK4 Uniprot Gene Name
    1019 Entrez Gene Id
    ENSG00000135446 Ensembl Gene Id

    Gene Info:
    Interpro Type Domain
    Uniprot Status Swiss-Prot
    Interpro Name Serine/threonine- / dual-specificity protein kinase, catalytic domain

    Gene Categories:
    KINASE, DRUGGABLE GENOME

    Publications:

  • RussLampel: ENSG00000135446

    • Version: 26-July-2011

    Alternate Names:
    CELL DIVISION PROTEIN KINASE 4 (EC 2.7.1.37) (CYCLIN-DEPENDENT KINASE 4) (PSK-J3). [SOURCE:UNIPROT/SWISSPROT;ACC:P11802] Description
    ENSG00000135446 Ensembl Gene Id
    CDK4 Display Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • CancerCommons: CDK4

    • Version: 25-July-2013

    Alternate Names:
    1019 Entrez Gene ID

    Gene Info:
    CancerCommons Reported Gene Name CDK4/6
    CancerCommons Reported Gene Name Pan CDK

    Publications:

  • BaderLabGenes: CDK4

    • Version: February-2014

    Alternate Names:
    1019 Entrez Gene ID

    Gene Info:
    Initial Gene Query CDK4
    Counted Citations from 1950-2000 3030

    Gene Categories:
    KINASE

    Publications:

  • TdgClinicalTrial: P11802

    • Version: January-2014

    Alternate Names:
    CDK4 Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:2.7.11.22

    Publications:

  • PharmGKB: CDK4

    • Version: 18-August-2020

    Alternate Names:
    PA102 PharmGKB ID

    Gene Info:

    Publications:
    Stevens A et al., 2014, Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome., Pharmacogenomics J

  • CIViC: CDK4

    • Version: 14-September-2020

    Alternate Names:
    1019 Entrez Gene ID
    13 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:
    Olanich ME et al., 2015, CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma., Clin Cancer Res
    Dickson et al., 2013, Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma., J. Clin. Oncol.
    Dickson et al., 2016, Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial., JAMA Oncol

  • NCI: CDK4

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Grillo et al., 2006, Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression., Breast Cancer Res. Treat.
    Hu et al., 2001, Differential effects of transforming growth factor on cell cycle regulatory molecules in human myeloid leukemia cells., Oncogene
    Banerji et al., 2005, Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models., Clin. Cancer Res.

  • DTC: CDK4

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Burgess A et al., 2006, Inhibition of S/G2 phase CDK4 reduces mitotic fidelity., J Biol Chem
    Montagnoli A et al., 2008, A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity., Nat Chem Biol
    Reddy MV et al., 2014, Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)., J Med Chem

  • HingoraniCasas: ENSG00000135446

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000135446 Gene Symbol
    CDK4 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • MyCancerGenome: CDK4

    • Version: 20-Jun-2017

    Alternate Names:
    1019 Entrez Gene Id
    CDK4 MyCancerGenome Gene Symbol
    CDK 1,2,4,5,6,7,9 (pan-CDK) MyCancerGenome Reported Gene Name

    Gene Info:

    Publications:

  • TALC: CDK4

    • Version: 12-May-2016

    Alternate Names:
    CDK4 Gene Symbol

    Gene Info:

    Publications:

  • ChemblInteractions: CDK4

    • Version: chembl_23

    Alternate Names:
    CDK4 GENE_SYMBOL
    Cyclin-dependent kinase 4 UNIPROT
    Cell division protein kinase 4 UNIPROT

    Gene Info:

    Publications:

  • OncoKB: CDK4

    • Version: 23-July-2020

    Alternate Names:
    1019 OncoKB Entrez Id
    PSK-J3 OncoKB Gene Synonym
    CMM3 OncoKB Gene Synonym

    Gene Info:

    Publications:

  • Tempus: CDK4

    • Version: 11-November-2018

    Alternate Names:
    CDK4 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • dGene: CDK4

    • Version: 27-Jun-2013

    Alternate Names:
    1019 Gene ID
    CMM3 dGene Synonym
    PSK-J3 dGene Synonym

    Gene Info:

    Gene Categories:
    KINASE, SERINE THREONINE KINASE

    Publications:

  • TTD: Cyclin-dependent kinase 4

    • Version: 2020.06.01

    Alternate Names:
    CDK4 TTD Gene Abbreviation
    T85799 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: CDK4

    • Version: 01-February-2022

    Alternate Names:
    Cyclin-dependent kinase 4 Gene Name
    P11802 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE, TRANSCRIPTION FACTOR

    Publications:

  • ClearityFoundationClinicalTrial: CDK4

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • MyCancerGenomeClinicalTrial: CDK4

    • Version: 30-February-2014

    Alternate Names:

    Gene Info:

    Publications:

  • ClearityFoundationBiomarkers: CDK4

    • Version: 26-July-2013

    Alternate Names:

    Gene Info:

    Publications:

  • MskImpact: CDK4

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FoundationOneGenes: CDK4

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: CDK4

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • GO: CDK4

    • Version: 01-February-2022

    Alternate Names:

    Gene Info:

    Gene Categories:
    TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR

    Publications:

  • Oncomine: CDK4

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21